UBS: Hansoh Pharmaceutical (03692.HK) Ris-Rez treatment for relapsed small cell lung cancer study results are encouraging; rating "Buy"

Zhitong Finance APP has learned that UBS released a research report stating that Hansoh Pharmaceutical's (03692.HK) B7-H3-targeting antibody-drug conjugate (ADC) Ris-Rez achieved positive results in a Phase III study for the treatment of relapsed small cell lung cancer (SCLC), with improvements in survival and tumor control, and fewer treatment-related adverse events, making the efficacy encouraging compared with the control group. The bank gave Hansoh Pharmaceutical a "Buy" rating with a target price of HKD 50.8.